Relmada Therapeutics

Relmada Therapeutics(RLMD)

CORAL GABLES, FL
Biotechnology

Focus: Small Molecules for Pain

Relmada Therapeutics is a life sciences company focused on Small Molecules for Pain.

OncologyNeurology
Funding Stage
PUBLIC
Employees
5000+
Open Jobs
0

Pipeline & Clinical Trials

Clinical Trials (1)
NCT06009003Individual Patient Esmethadone (REL-1017) Expanded Access Program
N/A
Phase 1
Clinical Trials (1)
NCT03637361Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone)
Phase 1
Phase 1
Clinical Trials (1)
NCT03638869Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone)
Phase 1
Clinical Trials (1)
NCT03051256Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
Phase 2
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
Non Muscle Invasive Bladder Cancer
Phase 2
Clinical Trials (1)
NCT06663137Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC
Phase 2
Clinical Trials (1)
NCT05081167A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
Phase 3
Clinical Trials (1)
NCT04855760Safety of REL-1017 for Major Depressive Disorder
Phase 3
Clinical Trials (1)
NCT04688164A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
Phase 3
Clinical Trials (1)
NCT07342517A Phase 3 Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
Phase 3
Clinical Trials (1)
NCT07313891A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2007
Portfolio: 10 clinical trials
SEC Filings: 2 available

Financials (FY2024)

R&D Spend
$55M52%
Net Income
-$99M
Cash
$4M